Table 6 Relative expression of mRNA levels in tumor samples after ex vivo exposure to topotecan and irinotecan. The IC50 concentrations for the samples tested are shown for each drug (median and range). The p values have been calculated using non-parametric statistics, in detail the Wilcoxon matched pairs test. On statistical advice, we chose not to use a Bonferroni's correction, but it should be noted that some technically statistically significant results could have arisen by chance.
| Â | Ovarian samples | Colorectal samples | ||||||
|---|---|---|---|---|---|---|---|---|
Target gene | n | Control | Topotecan IC50 = 0.754 μM (0.164–4.82) | p | n | Control | Irinotecan IC50 = 55.4 μM (29.5–100) | p |
BCRP | 9 | 0.0156 | 0.0125 | >0.999 | 7 | 0.0354 | 0.0515 | 0.6875 |
COX-2 | 10 | 0.253 | 0.475 | 0.7695 | 7 | 105.17 | 38.49 | 0.0156 |
EGFR | 10 | 0.470 | 0.163 | 0.0039 | - | - | - | - |
ERCC1 | 10 | 0.252 | 0.399 | 0.002 | 7 | 1.403 | 2.469 | 0.0156 |
MDR1 | 9 | 0.0090 | 0.0034 | 0.5703 | 7 | 0.2253 | 0.2938 | >0.999 |
MLH1 | 10 | 0.263 | 0.2268 | 0.0371 | - | - | - | - |
MRP1 | - | - | - | - | 7 | 5.132 | 3.775 | 0.0156 |
TOPO I | 10 | 4.490 | 2.448 | 0.0371 | 7 | 1.468 | 1.119 | 0.1094 |
TOPO IIα | 10 | 1.093 | 0.0670 | 0.002 | 6 | 0.2847 | 0.0733 | 0.2188 |
TOPO IIβ | - | - | - | - | 7 | 0.7405 | 0.5058 | 0.0313 |